# DESCRIPTION

## FIELD OF INVENTION

- introduce IL-1 receptor antagonist protein

## BACKGROUND OF INVENTION

- introduce IL-1
- describe IL-1 effects
- introduce IL-1R antagonist protein
- describe therapeutic approaches
- introduce peptides with IL-1R antagonist activity
- describe recombinant IL-1R antagonist protein
- describe drawbacks of anakinra
- introduce WO05086695A2 patent family
- describe peptide fragments of IL-1R antagonist protein
- describe advantages of short peptides

## SUMMARY OF INVENTION

- introduce truncated forms of IL1RA
- describe binding to IL-1R1
- describe inhibitory effect on IL-1 downstream signalling
- describe positive effect on neurite outgrowth and cell survival
- describe treatment of inflammatory disorders

## DEFINITIONS AND ABBREVIATIONS

- define IL1RA
- define IL1R1
- define affinity
- define Ilantafin/Ilantide
- define individual
- define polypeptide
- define isolated polypeptide
- define amino acid residue
- define equivalent amino acid residue
- classify equivalent amino acids
- define bioactive agent
- define drug
- define medicament
- define treating
- define treatment
- define therapy
- define treatment effect
- define pharmacologically effective amount
- define enhancing
- define co-administering
- define individual in need thereof
- define kit of parts
- describe molecular weights and lengths of polymers
- describe imprecision of standard analytical methods
- describe approximate values
- describe accuracy of values

## DETAILED DESCRIPTION OF THE INVENTION

### Inflammation

- define inflammation
- classify inflammation types

### Interleukins

- introduce interleukins
- describe interleukin function
- motivate IL-1
- describe IL-1 alpha
- detail IL-1 alpha structure
- describe IL-1 alpha production
- list IL-1 alpha producing cells
- describe IL-1 alpha regulation
- motivate IL-1 beta
- describe IL-1 beta production
- describe IL-1 receptor antagonist protein
- compare IL-1 beta and IL-1RA
- describe IL-1 receptors
- detail IL-1 receptor structure
- describe IL-1 receptor function

### Peptide Fragments of the Present Invention

- introduce truncated forms of IL1RA
- describe improved properties over full-length IL1RA protein and anakinra
- explain increased solubility
- explain increased stability
- explain lower cost of synthesis
- describe retention of ability to bind to IL-1R1
- describe interference with binding of IL-1 beta to IL-1R1
- describe desirable downstream effects
- explain better passage across blood-brain barrier
- describe positive effect on neurite outgrowth and neuronal cell survival
- define blood-brain barrier
- describe function of blood-brain barrier
- explain correlation between molecular weight and penetration
- introduce peptide comprising SGRKSSKMQA (SEQ ID NO:1)
- define fragment or variant thereof
- introduce peptides comprising RIWDVNQKT (SEQ ID NO:29), TAMEADQPVS (SEQ ID NO:35), or GPNA
- describe specific peptides
- describe preferred embodiment of specific peptides
- describe functional fragment or variant
- explain standard one-letter code for amino acid residues
- explain standard three-letter code for amino acid residues
- describe C-terminal amino acid
- describe N-terminal amino acid
- describe peptide comprising at least 5 of 20 proteinogenic amino acids
- describe peptide comprising unnatural amino acids
- describe preferred embodiment of peptide length
- describe fragment of peptide
- describe variant of peptide
- explain sequence identity
- describe calculation of sequence identity
- describe conservative substitutions
- describe non-conservative substitutions
- describe substitution of amino acids
- describe specific substitutions
- describe addition of amino acids
- describe modification of peptide sequence
- describe posttranslational modifications
- describe isolated peptide

### Synthetic Preparation

- describe methods for synthetic production of peptides
- describe specific methods for peptide synthesis

### Compound of the Present Invention

- describe compound comprising or consisting of a peptide according to the present invention

### Multimeric Compound

- define multimeric compound
- describe dimer embodiment
- describe trimer and tetramer embodiments
- describe dendrimer embodiment

### Methods

- describe methods for stimulating neurite outgrowth and/or promoting survival of neurons

### Pharmaceutical Formulation

- introduce pharmaceutical formulation
- describe solid form preparations
- describe liquid form preparations
- describe parenteral administration
- describe topical delivery
- describe transdermal administration
- describe lotions for eye application
- describe formulations for nasal, pulmonary and/or bronchial administration
- describe aerosol particle
- describe mechanical devices for administration
- describe liquid aerosol formulations
- describe dry powder formulations
- describe powder-filled capsules
- describe propellant materials
- describe pH maintenance and solution stabilization
- describe pharmaceutically acceptable salts
- describe administration routes

### Dosage

- define dosage requirements
- describe factors affecting dosage
- provide daily parenteral dosage regimen
- specify dosage ranges
- describe frequency of administration
- introduce unit dosage form concept
- define effective amount and effective level
- describe inter-individual differences in pharmacokinetics
- describe inter-individual differences in drug distribution
- describe inter-individual differences in metabolism
- provide example of effective level definition
- describe blood or tissue level desired
- describe concentration of compound according to invention
- motivate parenteral administration
- describe oral administration limitations
- describe advantages of parenteral administration
- describe different parenteral administration routes
- describe intravenous administration
- describe intramuscular administration
- describe subcutaneous administration
- describe inhalation administration
- describe topical administration
- motivate peptide administration
- describe peptide solubility
- describe peptide aggregation potential
- describe intranasal administration
- describe subcutaneous administration of peptide
- motivate co-administration
- describe co-administration with anti-inflammatory drugs
- describe co-administration with anti-rheumatoid drugs
- describe co-administration with anti-neurodegenerative drugs
- describe optimization of treatment outcome
- introduce kit-of-parts concept
- describe kit components
- motivate treatment of inflammatory disorders
- describe IL-1 role in inflammation
- describe IL-1 effects on immune system response
- describe IL-1 effects on fibroblasts proliferation
- describe IL-1 effects on proteases synthesis
- describe IL-1 effects on acute phase proteins synthesis
- describe IL-1 effects on blood neutrophils and lymphocyte proliferation
- introduce Behçet's disease
- describe symptoms of Behçet's disease
- motivate treatment of Behçet's disease
- introduce neurodegenerative disorders
- describe neurodegenerative disorders
- motivate treatment of neurodegenerative disorders
- introduce IL-1 system in neurodegeneration
- describe IL-1 system in neurodegeneration
- motivate blocking IL-1 signaling
- introduce Alzheimer's disease
- describe Alzheimer's disease
- motivate treatment of Alzheimer's disease
- introduce Parkinson's disease
- describe Parkinson's disease
- motivate treatment of Parkinson's disease
- introduce Huntington's disease
- describe Huntington's disease
- motivate treatment of Huntington's disease
- introduce Multiple sclerosis
- describe Multiple sclerosis
- motivate treatment of Multiple sclerosis
- introduce Interleukin-1 receptor antagonist protein
- describe amino acid sequence of Interleukin-1 receptor antagonist protein
- introduce UniProt Accession No.
- describe isoforms of Interleukin-1 receptor antagonist protein
- introduce Ilantafin-8/Ilantafin sequence
- introduce further Ilantafin-Sequences
- describe Ilantafin-1 sequence
- describe Ilantafin-2 sequence
- describe Ilantafin-3 sequence
- describe Ilantafin-4 sequence
- describe Ilantafin-5 and Ilantafin-6 sequences

## EXAMPLES

### Example 1

- locate Ilantafin sequence motif

### Example 2

- bind Ilantafin peptide to IL1RI
- analyze binding affinity

### Example 3

- inhibit macrophage activation
- verify sequence specificity

### Example 4

- inhibit IL1β-induced macrophage activation
- analyze dose-dependent response

### Example 5

- induce neurite outgrowth in primary neurons
- analyze dose-dependent response
- compare with IL1Ra and IL1RI
- analyze IL1β inhibition

### Example 6

- reduce neuronal cell death
- compare with IGF-1

### Example 7

- abrogate CIA in rats
- analyze clinical manifestations
- evaluate peptide efficacy

### Example 8

- detect Ilantafin peptides in plasma
- detect Ilantafin peptides in CSF
- analyze peptide penetration

### Example 9

- evaluate Ilantafin in reversing neuronal cytotoxicity
- treat hippocampal neurons with Ilantafin
- add kainic acid
- fix and stain cells
- estimate cell viability
- analyze nuclear morphology
- record cell viability
- estimate live cell ratio
- analyze SEM
- compare with full-length IL1RA
- evaluate Ilantafin efficacy
- analyze results

